Price
$3.2
Decreased by -0.31%
Dollar Volume
77.99 K
ADR%
5.82
Earnings Report Date (estimate)
Feb 28, 23 (-0.73)
Market Cap.
9.14 M
Shares Float
2.58 M
Shares Outstanding
2.86 M
Beta
0.91
Price / Earnings
-10.13
BPR
10.63
20D Range
2.71 3.50
50D Range
2.38 3.50
200D Range
2.38 11.07
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 -0.82
Decreased by -1.07 K%
-0.91
Increased by +9.89%
Aug 9, 22 -0.90
Decreased by -800.00%
-0.85
Decreased by -5.88%
May 12, 22 -0.05
Decreased by -66.67%
-0.08
Increased by +37.50%
Jan 12, 22 -0.08
Increased by +42.86%
-0.05
Decreased by -60.00%
Nov 29, 21 -0.07
Increased by +65.00%
-0.10
Increased by +30.00%
Jul 12, 21 -0.10
Increased by +62.96%
-0.09
Decreased by -11.11%
Apr 13, 21 -0.03
Increased by +92.50%
-0.11
Increased by +72.73%
Jan 14, 21 -0.14
Increased by +53.33%
-0.10
Decreased by -40.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 0.00
Decreased by N/A%
-2.33 M
Decreased by -23.50%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
-2.45 M
Decreased by -8.85%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
-1.97 M
Decreased by -5.31%
Decreased by N/A%
Decreased by N/A%
Nov 30, 21 0.00
Decreased by N/A%
-2.55 M
Decreased by -77.60%
Decreased by N/A%
Decreased by N/A%
Aug 31, 21 0.00
Decreased by N/A%
-1.89 M
Decreased by -40.43 K%
Decreased by N/A%
Decreased by N/A%
May 31, 21 0.00
Decreased by N/A%
-2.25 M
Decreased by -136.52%
Decreased by N/A%
Decreased by N/A%
Feb 28, 21 0.00
Decreased by N/A%
-1.87 M
Decreased by -36.19%
Decreased by N/A%
Decreased by N/A%
Nov 30, 20 0.00
Decreased by N/A%
-1.43 M
Decreased by -9.82%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.